These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29485449)

  • 1. Recurrent Medullary Thyroid Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT: Exploring New Theranostic Avenues.
    Arora S; Damle NA; Parida GK; Singhal A; Nalli H; Dattagupta S; Bal C
    Clin Nucl Med; 2018 May; 43(5):359-360. PubMed ID: 29485449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.
    Ciappuccini R; Edet-Sanson A; Saguet-Rysanek V; Gauthé M; Bardet S
    Clin Nucl Med; 2019 Aug; 44(8):663-665. PubMed ID: 31274618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
    Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
    Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
    Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
    Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
    Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
    Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 10. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
    Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
    Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
    [No Abstract]   [Full Text] [Related]  

  • 14. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
    Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.
    Hasenauer N; Higuchi T; Deschler-Baier B; Hartrampf PE; Pomper MG; Rowe SP; Fassnacht M; Buck AK; Werner RA
    Clin Nucl Med; 2022 Jul; 47(7):651-652. PubMed ID: 35085172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.